华蟾素胶囊联合紫杉醇、顺铂治疗中晚期宫颈癌的临床观察
发布时间：2019-05-15 17:30
【摘要】：目的:观察华蟾素胶囊联合紫杉醇、顺铂治疗中晚期宫颈癌的疗效和安全性。方法:92例中晚期宫颈癌患者随机分为对照组(46例)和观察组(46例)。两组患者均采用盆腔调强适形放射治疗+近距离放射治疗。在此基础上,对照组患者给予紫杉醇注射液135 mg/m~2,d1+顺铂注射液75 mg/m~2,d1,21 d为1个周期,放疗第1天开始化疗,放疗期间同步化疗2个周期。观察组患者在对照组治疗的基础上给予华蟾素胶囊0.5 g,口服,每日3次,于放疗当天开始口服,直至放疗结束。观察两组患者的临床疗效,治疗前后血小板、功能状态(KPS)评分、体质量,疼痛患者的缓解情况及血小板异常患者的恢复情况,并记录毒性反应发生情况。结果:观察组患者完全缓解率、血小板异常患者的恢复正常率、疼痛患者治疗3周后的缓解率及总缓解率均显著高于对照组,差异均有统计学意义(P0.05);两组患者总有效率及疼痛患者治疗4、5周后的缓解率比较,差异均无统计学意义(P0.05)。治疗后,两组患者血小板均显著低于同组治疗前,且观察组显著低于对照组;两组患者KPS评分及观察组患者的体质量均显著高于同组治疗前,对照组患者的体质量显著低于同组治疗前,且观察组显著高于对照组,差异均有统计学意义(P0.05)。观察组患者Ⅲ～Ⅳ级白细胞下降、恶心呕吐发生率,Ⅰ～Ⅱ级腹泻发生率均显著低于对照组,差异均有统计学意义(P0.05)。结论:在常规治疗的基础上,华蟾素胶囊联合紫杉醇、顺铂治疗中晚期宫颈癌的疗效显著,可改善患者血液高凝状态及生存质量,减轻疼痛,降低毒性反应的发生。
[Abstract]:Objective: to observe the efficacy and safety of cinobufagin capsule combined with paclitaxel and cisplatin in the treatment of advanced cervical cancer. Methods: 92 patients with advanced cervical cancer were randomly divided into control group (46 cases) and observation group (46 cases). Both groups were treated with pelvic intensity modulation conformal radiotherapy. On this basis, the patients in the control group were given paclitaxel injection 135 mg/m~2,d1 DDP injection 75 mg/m~2,d1,21 d for one cycle. Chemotherapy began on the first day of radiotherapy and synchronous chemotherapy during radiotherapy for 2 cycles. On the basis of treatment in the control group, the patients in the observation group were given cinobufagin capsule 0.5 g, oral three times a day, which began on the day of radiotherapy until the end of radiotherapy. The clinical efficacy, platelet, functional (KPS) score, body mass, relief of pain patients and recovery of abnormal platelet were observed before and after treatment, and the occurrence of toxic reaction was recorded. Results: the complete remission rate of the patients in the observation group, the recovery rate of abnormal platelets, the remission rate and the total remission rate of the pain patients after 3 weeks treatment were significantly higher than those in the control group, the difference was statistically significant (P 0.05). There was no significant difference in the total effective rate and pain relief rate between the two groups after 5 weeks (P 0.05). After treatment, the platelets in both groups were significantly lower than those in the same group before treatment, and the platelet in the observation group was significantly lower than that in the control group. The KPS score of the two groups and the body mass of the observation group were significantly higher than those of the same group before treatment, the body mass of the control group was significantly lower than that of the same group before treatment, and the observation group was significantly higher than the control group, the difference was statistically significant (P 0.05). The incidence of grade III ~ IV leukopenia, nausea and vomiting and grade 鈪，
本文编号：2477669
[Abstract]:Objective: to observe the efficacy and safety of cinobufagin capsule combined with paclitaxel and cisplatin in the treatment of advanced cervical cancer. Methods: 92 patients with advanced cervical cancer were randomly divided into control group (46 cases) and observation group (46 cases). Both groups were treated with pelvic intensity modulation conformal radiotherapy. On this basis, the patients in the control group were given paclitaxel injection 135 mg/m~2,d1 DDP injection 75 mg/m~2,d1,21 d for one cycle. Chemotherapy began on the first day of radiotherapy and synchronous chemotherapy during radiotherapy for 2 cycles. On the basis of treatment in the control group, the patients in the observation group were given cinobufagin capsule 0.5 g, oral three times a day, which began on the day of radiotherapy until the end of radiotherapy. The clinical efficacy, platelet, functional (KPS) score, body mass, relief of pain patients and recovery of abnormal platelet were observed before and after treatment, and the occurrence of toxic reaction was recorded. Results: the complete remission rate of the patients in the observation group, the recovery rate of abnormal platelets, the remission rate and the total remission rate of the pain patients after 3 weeks treatment were significantly higher than those in the control group, the difference was statistically significant (P 0.05). There was no significant difference in the total effective rate and pain relief rate between the two groups after 5 weeks (P 0.05). After treatment, the platelets in both groups were significantly lower than those in the same group before treatment, and the platelet in the observation group was significantly lower than that in the control group. The KPS score of the two groups and the body mass of the observation group were significantly higher than those of the same group before treatment, the body mass of the control group was significantly lower than that of the same group before treatment, and the observation group was significantly higher than the control group, the difference was statistically significant (P 0.05). The incidence of grade III ~ IV leukopenia, nausea and vomiting and grade 鈪，
本文编号：2477669
本文链接：https://www.wllwen.com/yixuelunwen/fuchankeerkelunwen/2477669.html
最近更新
教材专著
